Clinical research

Clinical and pathological characteristics as well as prognostic analysis of breast cancer patients with brain metastases

  • Juncheng SU ,
  • Yuzheng WANG ,
  • Lei TANG ,
  • Yingchun XU ,
  • Fengchun ZHANG
Expand
  • 1.Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215127, China
TANG Lei, E-mail: Bobbytang_1982@163.com.
XU Yingchun, E-mail: xiaoxu2384@163.com

Received date: 2022-04-15

  Accepted date: 2022-07-02

  Online published: 2023-01-04

Supported by

National Nature Science Foundation of China(81301858);Suzhou Science and Technology Project(SYS201404);Natural Science Foundation of Jiangsu Province(BK20181186)

Abstract

Objective ·To explore clinical and pathological characteristics, prognosis and potential related factors of breast cancer patients with brain metastases. Methods ·Seventy-five female breast cancer patients with brain metastases admitted to Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 2007 to December 2021 were selected. The clinical and pathological characteristics of the patients were collected through clinical electronic cases, and the overall survival after brain metastases (OSBM) of the patients was collected during the follow-up period. Receiver operating characteristic curve (ROC curve) was used to evaluate the predictive efficiency of different biochemical factors on OSBM. Kaplan-Meier survival curve was used to analyze the correlation between different clinical and pathological characteristics and patients' OSBM. Cox proportional hazards regression analysis was further performed on statistically significant factors to determine independent influencing factors. Results ·The OSBM of 75 patients was 11.0 (5.0, 24.0) months. The results of ROC curve showed that carbohydrate antigen 125 (CA125) had a good prediction effect on OSBM, and its best cut-off value was 22.3 U/mL. The results of Kaplan-Meier survival analysis showed that the patients whose first metastatic site was brain (P=0.046), whose extracranial disease status was progressed (P=0.042), whose brain metastasis involved one side of tentorium (P=0.013), whose CA125 level<22.3 U/mL (P=0.000), whose treatment methods incladed regional therapy (P=0.034) and whose modified Graded Prognostic Assessment (mGPA) score>1 (P=0.001), had longer OSBM. Cox proportional hazards regression analysis showed that brain metastasis involving both sides of tentorium or meningeal (P=0.029), and CA125 level≥22.3 U/mL (P=0.005) were the risk factors for OSBM, and mGPA score>1 (P=0.033) was the protective factor. Conclusion ·The position of brain metastases in breast cancer, the level of CA125 and the mGPA score are important factors affecting the prognosis of patients.

Cite this article

Juncheng SU , Yuzheng WANG , Lei TANG , Yingchun XU , Fengchun ZHANG . Clinical and pathological characteristics as well as prognostic analysis of breast cancer patients with brain metastases[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(11) : 1562 -1568 . DOI: 10.3969/j.issn.1674-8115.2022.11.007

References

1 SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
2 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志, 2020, 42(10): 781-797.
2 Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Cancer Expert Committee of China Anti-Cancer Association, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)[J]. Chinese Journal of Oncology, 2020, 42(10): 781-797.
3 MILLS M N, FIGURA N B, ARRINGTON J A, et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments[J]. Breast Cancer Res Treat, 2020, 180(2): 279-300.
4 GASPAR L, SCOTT C, ROTMAN M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J]. Int J Radiat Oncol Biol Phys, 1997, 37(4): 745-751.
5 WELTMAN E, SALVAJOLI J V, BRANDT R A, et al. Radiosurgery for brain metastases: a score index for predicting prognosis[J]. Int J Radiat Oncol Biol Phys, 2000, 46(5): 1155-1161.
6 LORENZONI J, DEVRIENDT D, MASSAGER N, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems[J]. Int J Radiat Oncol Biol Phys, 2004, 60(1): 218-224.
7 SPERDUTO C M, WATANABE Y, MULLAN J, et al. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment[J]. J Neurosurg, 2008, 109 Suppl: 87-89.
8 SPERDUTO P W, KASED N, ROBERGE D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J]. J Clin Oncol, 2012, 30(4): 419-425.
9 SPERDUTO P W, MESKO S, LI J, et al. Beyond an updated graded prognostic assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today[J]. Int J Radiat Oncol Biol Phys, 2020, 107(2): 334-343.
10 HOSONAGA M, SAYA H, ARIMA Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer[J]. Cancer Metastasis Rev, 2020, 39(3): 711-720.
11 ZAGAR T M, VAN SWEARINGEN A E, KAIDAR-PERSON O, et al. Multidisciplinary management of breast cancer brain metastases[J]. Oncology (Williston Park), 2016, 30(10): 923-933.
12 ASSI H I, MAHMOUD T, SAADEH F S, et al. Management of leptomeningeal metastasis in breast cancer[J]. Clin Neurol Neurosurg, 2018, 172: 151-159.
13 ETHIER J L, DESAUTELS D, TEMPLETON A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res, 2017, 19(1): 2.
14 LI J X, LIU L Y, FENG Z W, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study[J]. Breast Cancer, 2020, 27(4): 621-630.
15 ZENG Y C, WU R, WANG S L, et al. Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy[J]. Med Oncol, 2014, 31(7): 48.
16 WANG H, SHEN L H, GENG J H, et al. Prognostic value of cancer antigen-125 for lung adenocarcinoma patients with brain metastasis: a random survival forest prognostic model[J]. Sci Rep, 2018, 8: 5670.
17 张佳玲, 张凤春, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
17 ZHANG J L, ZHANG F C, XU Y C. Research progress in the systemic treatment for breast cancer with brain metastasis[J]. J Shanghai Jiao Tong Univ (Med Sci), 2021, 41(5): 671-677.
Outlines

/